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Frequent alterations in cytoskeleton remodelling
genes in primary and metastatic lung
adenocarcinomas
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The landscape of genetic alterations in lung adenocarcinoma derived from Asian patients is
largely uncharacterized. Here we present an integrated genomic and transcriptomic
analysis of 335 primary lung adenocarcinomas and 35 corresponding lymph node metastases
from Chinese patients. Altogether 13 signiﬁcantly mutated genes are identiﬁed, including the
most commonly mutated gene TP53 and novel mutation targets such as RHPN2, GLI3 and
MRC2. TP53 mutations are furthermore signiﬁcantly enriched in tumours from patients
harbouring metastases. Genes regulating cytoskeleton remodelling processes are also
frequently altered, especially in metastatic samples, of which the high expression level of
IQGAP3 is identiﬁed as a marker for poor prognosis. Our study represents the ﬁrst large-scale
sequencing effort on lung adenocarcinoma in Asian patients and provides a comprehensive
mutational landscape for both primary and metastatic tumours. This may thus form a basis
for personalized medical care and shed light on the molecular pathogenesis of metastatic lung
adenocarcinoma.
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L
ung cancer is the leading cause of cancerous deaths
worldwide1,2 with two major types: non-small-cell lung
cancer (NSCLC) and small cell lung cancer (SCLC),
accounting for B85% and 15% of all diagnosed lung cancers,
respectively3. Lung adenocarcinoma is the most common
histological type of NSCLC, resulting in 4500,000 deaths
globally every year4. Despite advances in surgery, molecular
subtyping and targeted therapy, prognosis of lung
adenocarcinoma remains poor and the reasons for this could be
due to: (1) Diagnosis was often made already at a late stage when
localized malignant tumours spread to regional and distant
tissues3; (2) Lack of known targetable driver genes in
approximately half of the diagnosed patients5,6; (3) Complexity
of inter- and intra-tumour heterogeneity7,8; and (4) Poor
understanding on the mechanism of metastasis development, as
well as lack of corresponding treatment.
Previous studies have characterized the genomic landscape of
lung adenocarcinomas and identiﬁed many potential cancer
driver genes4,9–11, of which targeting therapies have been
developed for several activated oncogenes such as EGFR, ERBB2
and BRAF6,12–14 and translocations or fusions involving ALK,
ROS1 and RET15–17. Most of these studies, however, mainly
focused on tumour samples obtained from European or North
American patients, and the majority of specimens were collected
at early disease stages. Undoubtedly, it is important to have a
comprehensive genomic analysis on lung adenocarcinomas from
Eastern Asian population when considering its rapidly increasing
incidence rate and potential genetic heterogeneity between
different ethnic populations. Moreover, genetic characterization
of advanced lung adenocarcinomas especially those harbouring
corresponding metastases will not only expand the spectrum of
potential cancer driver genes involved in lung carcinogenesis,
but also improve our knowledge on metastasis formation
and further guide diagnosis and therapies for metastatic
lung adenocarcinomas. A recent study demonstrated high
concordance of recurrent somatic alterations between primary
tumours and matched metastases in NSCLCs18. This initial
survey was limited though by focusing on targeted sequencing of
189 cancer-related genes.
Here we performed a comprehensive genetic analysis of 101
Chinese lung adenocarcinomas, as well as 35 corresponding
lymph node metastases through multiplatform sequencing. Two
hundred and thirty-four primary tumours were furthermore
included into this study as an independent validation cohort. In
an addition to a number of previously reported lung cancer driver
genes, we have identiﬁed several novel, potentially oncogenic
genes that are signiﬁcantly mutated in our cohort. Integrative
analyses through genomic data furthermore highlight pathways
that may play a critical role in driving tumour metastasis. These
results provide new insights on the pathogenesis of lung
adenocarcinomas and also form a basis for further improve-
ment of clinical management of our patients in the precision
medicine era.
Results
Sample description and sequencing statistics. Paired tumours
and normal adjacent tissues were obtained from 335 patients that
provided written informed consent to carry out genomic studies
in accordance with local Institutional Review Boards. All tumour
specimens were reviewed by independent pathologists to
determine the histological subtype, TNM stage and tumour
cellularity (Supplementary Fig. 1). Detailed clinical features were
summarized in Table 1 and Supplementary Data 1.
Whole-genome, transcriptome sequencing data were obtained
from primary tissues and corresponding lymph node metastases
of 24 Chinese lung adenocarcinoma patients. Genomes were
sequenced to a mean depth of 49.6 (range: 42.0–57.8 ) for
primary tumours and 51.2 (44.4–66.3 ) for metastatic
specimens, while it was 31.9 (range: 23.6–34.9 ) for adjacent
normal tissues. On average 93M clean reads (73–110M) were
generated from whole-transcriptome sequencing. Whole-exome
sequencing (WES) was performed on both primary and matched
lymph node metastases from an additional 11 cases, and from
primary tumour samples from a further group of 66 patients.
RNA-seq analysis was furthermore performed in 32 cases from
the latter group. Exome sequencing reached median fold coverage
of 81.4 (37.6–293.7 ) and 37.3M reads (20.0–53.4M) were
generated from RNA-seq (Supplementary Data 2 and 3). These
101 cases constituted the discovery cohort.
For veriﬁcation, an independent hybrid-recapture and
ultra-deep DNA sequencing were performed on a set of
51 selected genes with a mean fold coverage of 140
(48.2–455.1 ) on custom target regions in 98 cases of the
discovery cohort described above and additional 234 primary
lung adenocarcinomas (the validation cohort) (Supplementary
Data 4). The cohort description with different data sets was
summarized in Supplementary Data 5.
Somatic DNA alterations and veriﬁcation. Somatic point
variations and small insertions/deletions (indels; o50 bp) were
detected using MuTect19 and Platypus20, respectively. A mean of
9.7 somatic mutations per Mb (1.7–64.4) were identiﬁed from the
ﬁrst 101 primary lung adenocarcinomas, while the mean somatic
Table 1 | Clinical feature summary of 335 sequenced lung
adenocarcinomas.
Discovery
cohort
Validation
cohort
Total P value
Age at surgery,
years
0.4918w
Median 59.2 58.6 58.8
Range 25.2–81.6 32.4–84.9 25.2–84.9
Gender 0.1303z
Male 62 (61.4%) 121 (51.7%) 183 (54.6%)
Female 39 (38.6%) 113 (48.3%) 152 (45.4%)
Smoking status 0.3373z
Smoker 37 (36.6%) 68 (29.1%) 105 (31.3%)
Non-smoker 58 (57.4%) 141 (60.3%) 199 (59.4%)
NA 6 (5.9%) 25 (10.7%) 31 (9.3%)
Follow-up,
months
0.1042w
Median 22 37 36
Range 4–80 1–77 1–80
Tumour stage 0.1447z
I 19 (18.8%) 63 (26.9%) 82 (24.5%)
II 18 (17.8%) 51 (21.8%) 69 (20.6%)
III 56 (55.4%) 98 (41.9%) 154 (46%)
IV 8 (7.9%) 21 (9%) 29 (8.7%)
NA 0 (0%) 1 (0.4%) 1 (0.3%)
Metastasis 0.1087z
Negative 25 (24.8%) 80 (34.2%) 105 (31.3%)
Positive 76 (75.2%) 153 (65.4%) 229 (68.4%)
NA 0 (0%) 1 (0.4%) 1 (0.3%)
Survival status 0.3612z
Alive 67 (66.3%) 160 (68.4%) 227 (67.8%)
Dead 33 (32.7%) 60 (25.6%) 93 (27.8%)
NA 1 (1%) 14 (6%) 15 (4.5%)
NA, not applicable.
wWilcoxon rank sum test.
zPearson’s w2-test.
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mutation rate in 35 lymph node metastases was 6.4 mutations per
Mb (0.8–60.0) (Supplementary Data 6 and 7). A signiﬁcantly
higher mutation rate was observed in smokers (mutations per
Mb: mean 14.2, range 2.3–64.4) than in non-smokers (mutation
per Mb: mean 7.0, range 1.7–29.2, P¼ 0.0144, Wilcoxon rank
sum test) for primary tumours, while the mutation rate in
metastases was 9.2 (0.8–60.0) versus 4.7 (1.2–12.1) for smokers
and non-smokers, respectively.
Identiﬁed mutations were veriﬁed through two procedures.
First, mass spectrum was performed by using the MassArray
platform of Sequenom to validate 79 randomly selected
mutations, of which 76 (96.2%) were conﬁrmed (Supplementary
Data 8). Otherwise, ultra-deep target region sequencing on a set
of 51 selected genes was used to validate the mutations identiﬁed
in 98 primary tumours and 33 metastasis samples. In this
analysis, a total of 967 single nucleotide polymorphisms (SNPs)
and indels that passed pipeline ﬁlters were assayed, of which 960
were successfully veriﬁed, achieving a validation rate of 100% and
96% for single nucleotide variants (SNVs) and indel, respectively
(Supplementary Data 9).
Mutational signatures of lung adenocarcinomas. The somatic
mutation detection in our discovery cohort reveals a consistently
higher mutation rate in lung cancer than the other tumour
types except malignant melanoma, which links to exposure to
ultraviolet light21. Mutation spectrum analysis revealed that the
most common somatic substitutions in our discovery cohort were
C-A transversions and C-T transitions as previously reported
for lung adenocarcinomas4 (Supplementary Fig. 2). Mutational
signatures of 24 cases with whole-genome sequencing (WGS)
data were subsequently characterized on both primary and
metastatic tumours based on the 96 possible mutation types and
were compared with the WGS data derived from previously
reported European lung adenocarcinomas4. Four highly conﬁdent
mutational signatures were extracted from each sample set and
showed no apparent difference between primary and metastatic
samples (signature 1, 2, 3, 4) (Fig. 1). When compared with the
four signatures extracted from European lung adenocarcinomas,
highest correlation (Pearson Correlation 40.99) was detected in
signatures that were predominated by C4A mutations (Chinese
signature 1 and European signature 1) and associated with
cigarette smoking. The second highly correlated signature was
Chinese signature 3 to European signature 3 (Pearson correlation
40.95), which attributed to over-activated members of the
APOBEC family of cytidine deaminase. Indeed the expression
levels of APOBEC1, APOBEC3B, APOBEC3C and APOBEC3F
were found to be signiﬁcantly higher in both primary and
metastatic tumours as compared with normal tissues (Po0.01,
Supplementary Fig. 3). Similar analysis was also applied to 10
previously reported stage I Chinese lung adenocarcinomas with
WGS data22. Three high conﬁdent signatures from these tumours
were identiﬁed, which show high correlation with signature 1,
signature 3 and signature 4 that were extracted from 24
Chinese lung adenocarcinomas at late stage and 22 European
lung adenocarcinomas. This observation indicated the signiﬁcant
association of these three signatures with lung adenocarcinomas,
at both early and late stage of the disease, and they are shared
within different ethnic populations. It is notable that signature 2,
with transitions and transversions that predominantly occur at
ApNpA and TpNpT trinucleotides (Fig. 1), is speciﬁc to our
cohort that was not found in any of the 30 cancer types reported
before21 or in early stage lung adenocarcinoma. Furthermore,
the metastatic tumours seem to more often (46%, 11/24)
carry dominant proportion of ‘signature 2’ (with 420%
of contribution) as compared with the primary tumours (25%,
6/24). The contribution of ‘signature 2’ is highly correlated with
the proportion of indel mutations, as tumours carried signatures
with higher contribution of ‘signature 2’ also harboured
signiﬁcantly higher proportion of indel mutations in all somatic
mutations detected (Supplementary Fig. 4a). In contrast, the other
signatures do not show such linear association with indel
mutation. Since the mutational signature analysis was carried
out only using base substitutions, the association of indel
mutation of speciﬁc signature should not be attributed to
incorporation of indel mutations to the analysis. We then
veriﬁed our ﬁnding in the mutation data of 22 European lung
adenocarcinomas. We found that the contribution of ‘signature 2’
in these 22 European lung adenocarcinomas is only 4% on
average, signiﬁcantly lower than that in primary tumours (18%)
and metastatic tumours (22%) in our sequenced cohort
(Po0.001, Wilcoxin Signed Ranks Test). This explained that
why this signature was not evidently identiﬁed from the previous
analysis in the European sample set. However, we conﬁrmed that
in the European tumours, the contribution of ‘signature 2’ is also
highly correlated with the proportion of indel mutations
(Supplementary Fig. 4b). No germline or somatic mutations in
DNA repair genes including various mismatch repair genes,
BRCA1 and BRCA2 could explain the occurrence of ‘signature 2’.
Although this signature seems to be due to inclusion of large
number of late stage of lung adenocarcinoma patients with
metastasis in our study, WGS data in a larger cohort of patients
will be required to conﬁrm this association and to further
understand the underlying mutagenesis mechanism.
Distinct combinations of mutational signatures were observed in
each individual cancer, which indicated inter-tumour heterogeneity
(Supplementary Fig. 5a). It is interesting that though we identiﬁed
similar landscape of mutational signatures between primary and
metastatic sample sets, about 33% (8/24) cases showed different
contribution of signatures between the paired primary and
metastatic tumours, which may be attributed to intra-tumour
heterogeneity or mutational selection during metastases
(Supplementary Fig. 5b). No signiﬁcant correlation was observed
between the mutation signature distribution and patient age,
gender, smoking status or tumour purity (Supplementary Data 10),
which may be partially due to the limited sample size.
Signiﬁcantly mutated genes. Given the high level of background
mutation rate in lung cancer, oncogenic driver event analysis was
carried out through a modiﬁed pipeline described previously23,24,
which considered the mutation prevalence in the context of the
background mutation rate and gene sequence length, as well as
evaluation of functional impact. The MutSig25 algorithm was
subsequently applied to identify signiﬁcantly mutated genes and
the mutant frequency was calculated by integrating the discovery
and validation cohorts, for altogether 335 primary tumours and
35 metastasis specimens. These analyses revealed 13 statistically
signiﬁcant mutated genes (qo0.1, Fig. 2a, Supplementary Fig. 6,
Supplementary Data 11). The most frequently mutated genes in
primary tumours are TP53 (44%), EGFR (39%), LRP1B (19%) and
KRAS (11%), indicating the major contribution of these genes in
lung carcinogenesis. The other frequently mutated genes include
well-known tumour suppressor genes: PTPRD (7%), STK11 (4%)
and SMAD2 (2%), and oncogenes PIK3CA (5%), BRAF (4%) and
FLT1 (3%). Consistent with the previous studies, KRASmutations
are mutually exclusive with those of EGFR, and are more
commonly observed in smokers4,10,26. We also conﬁrmed a
higher mutation rate of EGFR than KRAS in our cohort, which is
in contrast to that in the Caucasian populations. Notably, 54%
(71/132) of the EGFR mutations are Leu858Arg, and another 29%
(39/132) EGFR mutations are exon 19 deletions, which are
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sensitive targets of tyrosine kinase inhibitor therapies12. This
conﬁrms the importance of testing these speciﬁc mutations for
Chinese lung adenocarcinoma patients.
Mutations in RHPN2 (5%), GLI3 (4%) and MRC2 (2%) have
not been reported previously as driver genes in lung adenocarci-
nomas but were recurrently observed in our cohort and are
nominated to be signiﬁcantly mutated. RHPN2, which encodes a
member of the rhophilin family of Ras-homologous (Rho)
GTPase-binding proteins, was ﬁrst identiﬁed to interact with
RhoA as a downstream effector molecule to regulate the actin
cytoskeleton27, a process that is involved in cancer cell migration
and invasion. A recent study further demonstrated that RHPN2
could drive mesenchymal transformation in malignant glioma via
triggering RhoA activation28. Notably, a novel but recurrent
mutation V73M was identiﬁed for RHPN2 (Supplementary
Fig. 6b), which affecting the Rho binding domain, implying
that this site could be a potentially functional important hotspot
mutation. GLI3 encodes a zinc-ﬁnger transcription factor that
modulates the sonic hedgehog (SHH) pathway, and one recent
study on NSCLC demonstrated that overexpression of truncated
GLI3 was signiﬁcantly associated with lymph node metastasis and
poor survival29. Another investigation also showed that high
expression of GLI3, together with GLI1, is associated with tumour
progression in advanced lung adenocarcinoma30. The exact
mechanism of GLI3 mutations in tumorigenesis and whether
the potentially affected SHH signalling could be targeted have not
been determined. MRC2 (also known as uPARAP, Endo180 or
CD280), a member of mannose receptor family, is found to be
involved in extracellular matrix remodelling by mediating
collagen degradation31,32. Functional experiments and clinical
surveys have demonstrated that high expression of MRC2 can
promote tumour growth and drive metastasis, results in
signiﬁcantly worse prognosis in several cancers33–36.
Additional recurrently mutated genes that did not reach a
statistical signiﬁcance by MutSig, but may functionally impact
carcinogenesis, were also identiﬁed. These include APC (5%),
KEAP1 (4%), ATF7IP (4%), ITIH5 (3%), IQGAP3 (3%), MET
(3%), ERBB2 (2%) and TERT (2%) (Fig. 2a, Supplementary
Fig. 6 and Supplementary Data 11), of which KEAP1 was
mutually exclusively mutated with EGFR. The mutation
frequencies of all the mutated genes described above in
metastatic specimens are also shown in Fig. 2a. It is interesting
to note that though KRAS was frequently mutated in primary
tumours, no mutations were called for this gene in the 35
sequenced metastases, including those 5 samples with paired,
KRAS-mutated primary tumours. The ﬁve metastatic tumours
with KRAS mutations ‘loss’ were ﬁrst conﬁrmed as geneti-
cally identical with the corresponding primary tumours, by
comparing both the pre-sequencing mass spectrometric
ﬁngerprint genotyping (Supplementary Data 12) and the
genome-wide SNPs called from sequencing data. Visual review
of the sequencing reads in these samples subsequently
conﬁrmed the sufﬁcient coverage of all mutated sites for high
quality mutation calling (Supplementary Data 13).Visual
inspection furthermore conﬁrmed that none of the normal
tissues carried any reads of the mutated KRAS allele. At most
two or three reads with mutation can be visualized, however,
from metastatic specimens, thus suggesting a signiﬁcantly lower
frequency (0.01 on average; range: 0–0.02) in the metastases as
compared with the corresponding primary tumours (0.30 on
average; range: 0.18–0.46). Sanger sequencing further showed
evident mutant genotype in primary tumours but no peak of
altered signal was detected either in normal tissues or metastatic
tumours.
The mutation patterns were further correlated with other
clinical features such as gender, smoking status, age and
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Figure 1 | Mutational signatures of lung adenocarcinoma. Comparison of signatures between primary and metastatic lung adenocarcinomas in this study
as well as lung adenocarcinomas derived from a previously published European cohort. Signatures were displayed according to the 96-substitution
classiﬁcation, with x-axes showed mutation types and y-axes showed trinucleotide frequency of each mutation type.
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tumour stage. The EGFR mutations were more frequently
observed in females, while mutations in LRP1B, KRAS,
PTPRD, APC, STK11, KEAP1, ITIH5 and FLT1 were signiﬁcantly
enriched in males (Po0.05, Fisher’s exact test). While
EGFR mutations were enriched in non-smokers, mutations of
LRP1B, KRAS, PTPRD, KEAP1 and GLI3 were signiﬁcantly
enriched in smokers (Po0.05, Fisher’s exact test). Notably, TP53,
GLI3 and ITIH5 were signiﬁcantly more mutated in patients aged
460 years (Po0.05, Fisher’s exact test) but none of the
recurrently mutated genes was associated with tumour stage
(Fig. 2b).
Metastasis is one of the most critical issues for disease
progression in lung adenocarcinoma, however, whether the
mutation patterns are different between tumours with or without
metastasis is yet to be studied. All the samples were thus classiﬁed
into two groups, those who had metastases in adjacent lymph
nodes or distant organs on diagnosis or surgery (PMþ , n¼ 229),
and those who were metastasis free at diagnosis (PM , n¼ 105).
This classiﬁcation was not associated with gender (P¼ 0.64),
smoking status (P¼ 0.79) or age (P¼ 0.08). Fisher’s exact test
indicated that TP53 was the only gene that was signiﬁcantly
(Po0.05) enriched in patients harbouring metastases (Fig. 2b),
suggesting an important role of this tumour suppressor gene not
only in primary tumorigenesis but also in driving the metastatic
process.
Kaplan–Meier survival analysis was performed in all patients
(n¼ 335) and validation cohort (n¼ 234), respectively, to explore
the potential association between the recurrently mutated genes
and individual outcome. Individuals harbouring somatic muta-
tions in TP53, LRP1B, STK11, KEAP1, BRAF, MET and MRC2
had signiﬁcantly shorter survival time than individuals with
wild-type genotypes (Supplementary Fig. 7), which suggested that
alterations in these genes could be used as prognostic markers in
clinical practice.
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and validation cohorts, comprising 335 primary tumours and 35 metastatic tumours. Primary tumours were classiﬁed into two groups: samples with
metastases in adjacent lymph nodes or distant organs on diagnosis or surgery (PMþ , n¼ 229), and samples which were metastasis free at the time for
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indicate genes predicted to be signiﬁcantly mutated by MutSig algorithm (FDRo0.1). (b) Associations of speciﬁc mutated genes with metastasis status,
gender, smoking status and age. Asterisks were marked at the sides of sample sets with signiﬁcantly higher mutant frequencies (Po0.05, Fisher’s exact test).
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Somatic CNVs and mRNA expression proﬁling. Somatic copy
number alterations (SCNAs) were proﬁled in the 101 primary
tumours and 35 metastases from the discovery cohort. The results
revealed frequent abnormalities of chromosomal arms involving
gain of 1q, 3q, 5p, 7p/q, 8q, 14q, 16p, 17q and 20q, as well as loss
of 3p, 4q, 6q, 8p, 9p, 12q, 13q, 15q, 17p and 18q (Supplementary
Fig. 8), most of which were consistent with previous results
reported in lung adenocarcinomas9. GSITIC37 was applied to
identify statistically signiﬁcant recurrent focal copy number
variants (CNVs) (Fig. 3a, Supplementary Data 14). Signiﬁcant
somatic ampliﬁcations of NKX2-1, TERT, EGFR, CCND1,MDM2,
CDK4, MET, MYC and MECOM were observed, as well as
deletion of TP53, PTPRD and CDKN2A/2B that have been widely
reported in lung adenocarcinoma. Signiﬁcantly ampliﬁed regions
that encompassed genes involved in cytoskeleton organization or
focal adhesion were also identiﬁed, including IQGAP3, TRIO,
FSCN1/FSCN2 (fascin homologue 1/2, actin-bundling protein),
RAC1/RAC3 and ITGB4/ITGB8. Recurrent, novel focal deletion
regions were furthermore detected affecting tumour suppressor
genes SMAD2 and SMAD4. Proﬁling of CNAs in metastatic
tumours additionally identiﬁed ampliﬁcation of SOX3 and deleted
regions affecting STK11, KEAP1 and MGA. It is interesting that
CNAs of several genes with function in histone or chromatin
modiﬁcation, such as KDM5B, CREBBP, SETD2, SMARCA4 and
MECP2 were also found either in primary or metastatic tumours,
suggesting a potential role of epigenetic regulation in lung
adenocarcinoma. Proﬁling of mRNA expression status of 56
tumour/adjacent normal pairs conﬁrmed correlated higher
expression level in genes with copy number ampliﬁcation than
those with deleted CNAs (Supplementary Fig. 9).
Unsupervized clustering analysis of gene expression data from
the 56 primary tumours identiﬁed three subgroups (cluster 1,
cluster 2 and cluster 3) (Fig. 3b). Kaplan–Meier survival analysis
indicated that cluster 3, which has higher frequencies of KRAS,
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FLT1, KEAP1 mutations and ampliﬁed CEP72, demonstrated a
signiﬁcantly shorter survival time than patients in the other two
clusters (Supplementary Fig. 10). We also found that several
genes participate in the PI3K–Akt pathway or cytoskeleton
remodelling process, such as PIK3CA, PKN2, PTK2, DOCK1,
SOS1 and MAPK1 had elevated expression status in cluster 3 as
compared with cluster 1 and cluster 2, implying the activation of
these processes may direct to disease progression (Fig. 3c).
Identiﬁcation of structural alterations. Taking advantage of
high depth WGS (50 coverage on tumour samples and 30
coverage for adjacent normal tissues) and corresponding tran-
scriptome sequencing of 24 cases with paired primary and
metastasis tumours sequenced, the structural alterations in lung
adenocarcinoma were characterized. A total of 2,287 and 1,910
somatic structural aberrations were detected from primary and
metastatic tumours, respectively (Supplementary Data 15 and
Supplementary Fig. 11). Among the translocation events in
primary tumours, 1,404 were inter-chromosomal (CTX), 201
were intra-chromosomal (ITX), 295 were inversions (INV) and
387 were deletions (DEL). The numbers of aberrant events in
metastases were 1,467 CTXs, 127 ITXs, 107 INVs and 211 DELs.
Well-known fusion genes EML4-ALK were identiﬁed in 2 out of
these 24 cases in both primary and metastatic tumours with
supportive evidence from both DNA and RNA data. Further
screening through targeted sequencing of all 335 cases revealed 7
additional tumours harbouring this gene–gene fusion, giving an
overall 3% alteration rate. Concurrent and mutual exclusion
analysis indicated that EML4-ALK fusion was mutually exclusive
with EGFR mutations (Supplementary Fig. 12), consistent with a
recent large-scale clinical screening of NSCLC for EGFR, KRAS
mutations and ALK rearrangements38. Previously reported
rearrangements of ROS1 and RET genes in NSCLC patients
were not observed in our patient cohorts.
We further identiﬁed additional 13 putative gene–gene
fusion events in these 24 metastatic cases using a combination
of the whole-genome and transcriptome sequencing data (Supple-
mentary Data 16, Supplementary Fig. 13). It is notable that
among these fusions, several genes that function in cytoskeleton
regulation were involved, including IQGAP3, EPB41, CDC42,
PARD6G, PTK2B and KALRN, suggesting that these alterations
may promote metastasis development. Other fused genes with
putative role in tumorigenesis or metastasis formation include
CHEK2, FGFR2, MIIP, CPB1, EIF4A2, MECOM and USP32.
Analysis of the IQGAP3 locus. Integrated analysis of somatic
mutations, CNAs, structural aberrations and gene–gene fusions
using multiplatform studies highlighted IQGAP3 was altered in a
notable number of cases. This gene, a member of the IQGAP
family that has both IQ motifs and Ras GTPase-activating
protein-related domain (GRD)39,40, was altered in 10% of lung
adenocarcinomas (discovery cohort, n¼ 101), by somatic
mutations (three cases), copy number ampliﬁcation (seven
cases) and translocation (one case). Targeted regional
sequencing of the validation cohort (n¼ 234) further identiﬁed
eight additional cases harbouring somatic mutations on IQGAP3.
Analysis of mRNA expression of 56 RNA sequenced primary
tumours and 24 RNA sequenced metastases revealed that
IQGAP3 was expressed at a signiﬁcantly higher level in tumour
specimens than adjacent normal tissues (Supplementary Fig. 14).
The IQGAP3 expression in 132 primary lung adenocarcinomas
(61 from discovery cohort and 71 from validation cohort) with
available RNA within the 335 sequenced cases was subsequently
measured by quantitative reverse transcription–PCR (RT–PCR;
Supplementary Data 17), and conﬁrmed the higher expression
level of IQGAP3 in these tumours (Fig. 4a). An elevated level of
IQGAP3 protein was also conﬁrmed in a subset of primary
tumours by immunohistochemical staining (n¼ 42, Po0.001,
Wilcoxin Signed Ranks Test, Supplementary Fig. 15).
Kaplan–Meier analysis indicated that patients with a higher level
of IQGAP3 mRNA had signiﬁcantly shorter overall survival and
disease-free survival (Fig. 4a, Supplementary Fig. 16). Further-
more, Multivariate Cox proportional hazard analysis showed that
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Figure 4 | Integrated characterizations of IQGAP3 alterations. (a)
Quantitative RT–PCR analysis of 132 lung adenocarcinoma patients showed
signiﬁcantly higher expression of IQGAP3 mRNA in tumours than in
adjacent normal tissues in lung adenocarcinoma patients. Kaplan–Meier
survival curves showed that patients with high IQGAP3 expression had
shorter overall survival. (b) Three-dimensional model of IQGAP3 protein
showing the somatic mutations affecting functional domains. qPCR analysis
in patients harbouring these mutations showed no signiﬁcant difference of
IQGAP3 expression between tumour and normal tissues. (c) Tumours
harbouring genomic ampliﬁcations of IQGAP3 in chromosome 1. QPCR
analysis indicated higher expression of IQGAP3 in corresponding tumours
with copy gain of IQGAP3 than in adjacent normal tissues.
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a higher level of IQGAP3 was an independent risk factor for poor
prognosis of the lung adenocarcinoma patients (Supplementary
Data 18 and 19, hazard ratio¼ 2.28, 95% conﬁdence
interval¼ 1.25–4.14, P¼ 0.007).
The association of IQGAP3 genetic alterations and mRNA
expression was subsequently investigated. No signiﬁcant differ-
ence was observed in IQGAP3 expression between tumours and
normal tissues in the eight cases carrying somatic mutations,
including four mutated sites located in the Ras GTPase-
Activating Protein (RasGAP) domain (Q1085H, A1124T,
D1164E and L1292 splicing site) and one truncated mutation
that resulted in the loss of the RasGAP C terminus domain
(Fig. 4b). Furthermore, patients harbouring IQGAP3 SNVs
showed better survival status than the other cases though did
not reach a statistical signiﬁcance (Supplementary Fig. 7). By
contrast, this gene was overexpressed in tumours affected by
copy number ampliﬁcations (Fig. 4c). An inter-chromosomal
rearrangement occurred between chromosome 17 and chromo-
some 1 was identiﬁed in patient WG04, in both primary and
metastasis tumours, which results in a novel gene–gene fusion
involving TMC6 and IQGAP3, with reversed 50 and 30 orientation
(Supplementary Fig. 17a). The fused product consists of exons
coding most of the RasGAP domain and the intact RasGAP C
terminus domain of IQGAP3, while retained exon 1 and exon 2
of TMC6. RNA-seq data revealed markedly higher, outlier
expression of IQGAP3 in primary and metastasis tumour of
patient WG04, and investigation of reads coverage indicated that
highly covered regions were enriched in exons containing
RasGAP and RasGAP C terminus domains (Supplementary
Fig.17b,c).
Altered key pathways and therapeutic targeting. Integrative
analysis of altered key pathways affected by somatic mutations,
CNAs as well as frequent rearrangements was performed to
construct a comprehensive view of aberrant characteristics for
lung adenocarcinoma (Fig. 5a). The most frequently altered
pathways in primary tumours were p53 signalling and cell cycle
process, affecting 87% of primary tumours and 89% of metastatic
tumours. A majority of the observed mutations were somatic
mutations in TP53, ampliﬁcations of MDM2, MYC, CCND1,
CCNE2, CDK4 and CDK6, as well as loss-of-function variants
including deletions of CDKN2A, CDKN2B, mutations and dele-
tions affecting SMAD2 and SMAD4, of which TP53 mutations
were mutually exclusive with MDM2 ampliﬁcation
(Supplementary Fig. 12). CHEK2, a serine/threonine-protein
kinase involved in regulating cell cycle arrest, was altered either
by somatic mutation, deletion or rearrangement. The RTK/Ras/
PI3K pathway was also frequently altered in lung adenocarci-
noma, with 88% of primary tumours and 80% of metastasis
tumours in this study harbouring aberrations in genes involved in
this pathway. Included were events affecting several therapeutic
targets that were responsive to antibodies or kinase inhibitors,
such as alterations of EGFR, PIK3CA, ALK, ERBB2, MET, AKT1
and mTOR (Fig. 6).
Speciﬁcally, an additional pathway that involves actin cytoske-
leton remodelling and focal adhesion was frequently altered in
lung adenocarcinoma, affecting 50% of primary tumours. In
addition to IQGAP3, ﬁve other genes with important roles in
cytoskeleton remodelling exhibited somatic mutations or copy
number ampliﬁcations, namely, RHPN2, RAC1, RAC3, TRIO and
CDC42. FSCN1 and FSCN2 were found to be frequently ampliﬁed
in our studied cohort. These two genes belong to the Fascin
protein family, which organizes F-actin into parallel bundles and
plays an important role in cell migration, motility, adhesion
and cellular interactions. Several studies have demonstrated a
modulating function of Fascin proteins, especially FSCN1 in
tumour metastasis and considered the overexpression of this gene
as a prognostic marker for aggressiveness in carcinomas41–43.
Network analysis further extended the interactive association
between genes and pathways (Fig. 5b) that promote regulation of
cytoskeleton remodelling. It is notable that this process was more
frequently in metastasis samples (77%) than primary tumours
(50%), implying the potential crucial contributions of these genes
in driving metastasis.
Discussion
Although lung adenocarcinoma is one of the most well-studied
cancers worldwide, the accuracy of diagnostic and therapeutic
effectiveness are far from satisfactory, especially for patients
harbouring metastases. In the present study, we carried out a
comprehensive genetic characterization of 335 lung adenocarci-
nomas by integrating WGS, WES and RNA-seq. Sixty-eight per
cent of studied cases were metastasis positive, providing an
opportunity for the investigation of potential mechanisms and
identifying biomarkers for driving metastasis.
Our study ﬁrst delineated the similarity and distinctive
mutational features of lung adenocarcinomas between Chinese
and Caucasians. We discovered signatures associated with
smoking and activation of APOBEC molecules that were shared
in tumours from both ethnic populations and also detected
signature speciﬁc to our cohort, which consists mainly late stage
lung adenocarcinomas and is associated with the proportion of
indel mutations. EGFR was mutated at a much higher frequency
in our cohort than in Caucasians, with a dominance of the
Leu858Arg change. By contrast, KRAS, the second most
commonly mutated gene in Caucasians, was only found in 11%
of Chinese patients. Notably, we observed signiﬁcantly lower
frequency or even loss of KRAS mutation in the metastatic
tumours as compared with their paired primary tumours. The
discordance of KRAS mutations in primary tumours and
corresponding metastases has been noted previously in a few
cases of lung adenocarcinomas44,45. Independent studies
demonstrated that oncogenic KRAS itself initiates the growth of
non-invasive tumours in mouse models of lung cancer46,47,
implying that KRAS mutations may induce tumorigenesis, but
might not be responsible for tumour metastasis, at least in some
cases. Alternative interpretation of such discordant observation
could attribute to tumoral heterogeneity, thus analysis of more
biopsies from both primary tumour and metastatic lymph nodes
from the same individuals may give a more complete picture48.
Our results suggest that alterations in major cancer drivers may
change during tumour evolution and the development of
metastasis, which should be important in clinical application,
for instance, it may not be sufﬁcient to determine therapeutic
strategy for metastatic tumours base solely on the mutation
spectrum in primary tumours.
We identiﬁed three genes, RHPN2, GLI3 and MRC2 to be
signiﬁcantly mutated in our studied cohort. These genes are
altered in lower frequency, therefore are not determined as driver
genes in lung adenocarcinoma previously. According to the
saturation analysis by Lawrence et al.49, the discovery of
candidate cancer genes is signiﬁcantly associated with the
sample set used and taking lung adenocarcinoma as an example
B2,000 cases are required to achieve a comprehensive catalogue
of cancer genes with sufﬁcient statistic power when the genes are
mutated in43% of patients. Our discovery of novel signiﬁcantly
mutated genes in lung adenocarcinoma conﬁrms the necessity of
continuous sequencing and analysis effort on more tumour-
normal pairs of cancer patients. Although our study presented the
potential association of these mutations to lung adenocarcinoma
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through bioinformatic exploratory analysis, functional study is
essential to demonstrate the exact mechanism of these mutated
genes in lung adenocarcinoma carcinogenesis in the future.
We also showed a signiﬁcant enrichment of TP53 mutations in
patients with metastases on diagnosis or surgery. TP53 was in fact
the most frequently mutated gene in many types of cancers.
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Emerging evidence indicates that mutant TP53 not only loses its
tumour-suppressing activity, but also can gain functions that
contribute to tumour progression50–53. Many mutations of TP53
have been implicated in invasion, migration and metastasis in
different tumour types (summarized in ref. 54).
Integrative pathway investigation revealed that the most
commonly altered processes are related to p53 signalling/cell
cycle progression and the RTK/Ras/PI3K (mTOR) pathways in
lung adenocarcinoma. Within this group of molecules are several
targets for kinase inhibitors that are successfully used for
treatment of patients with sensitive mutations. Furthermore, the
actin cytoskeleton remodelling process, along with genes involved
in focal adhesion was observed to be frequently altered in lung
adenocarcinoma. Among the mutated genes involved in cytoske-
leton remodelling, IQGAP3 was highlighted as numerous
different alterations were identiﬁed including a novel fusion
event. Clinical association analysis indicated that a high level of
IQGAP3 expression is a putative biomarker in disease progres-
sion and poor survival status, implicating IQGAP3 as a potentially
targetable gene for novel therapeutic strategies. Overall our study
provided the ﬁrst comprehensive description of mutational
landscape of lung adenocarcinoma in Chinese patients, deﬁned
potential mechanisms for cancer metastasis and provided a basis
for effective personalized therapies for this lethal cancer. Whether
the discovered novel genomic changes are speciﬁc for Asian
population and/or represent the disease heterogeneity, remains to
be further explored in larger sets of tumour samples.
Methods
Patients and clinical samples description. The primary tumour specimens,
adjacent normal tissues and lymph node metastases (if available) were obtained
from 335 patients with lung adenocarcinoma who underwent surgical resection in
Department of thoracic surgery, the First Afﬁliated Hospital of Guangzhou Medical
University. None of the patients were subjected to chemotherapy or radiotherapy
before surgery. Tumours and adjacent normal tissues were frozen in liquid nitrogen
and stored at  80 C for further research. The tumour specimens were reviewed
by two pathologists independently to determine the histological subtype, TNM
stage and tumour cellularity. The primary tumour tissues containing at least 50% of
tumour cells and the lymph node metastases with at least 30% of tumour cells were
included in this study. Detailed clinical characteristics were summarized in Table 1
and Supplementary Data 1. The routine follow-up was conducted every 3 months
and the median follow-up was 36 months. About 227 patients (68%) were alive at
the time of last follow-up. This study was approved by the Institutional Review
Board of the First Afﬁliated Hospital, Guangzhou Medical University, Guangzhou,
China. All patients who participated in this study provided written informed
consent.
Genomic DNA and total RNA preparation. The genomic DNA from tissues
was prepared using the QIAamp DNA Mini Kit (Qiagen) following the
manufacturer’s instructions. The total RNA was prepared using TRIzol Reagents
(Life Technologies). The quantity and quality of DNA/RNA were determined
by agarose gel electrophoresis or Agilent 2100 analyzer. Mass spectrometric
ﬁngerprint genotyping of 21 common SNPs was performed for all the samples
before sequencing, to verify that paired tumour (primary and metastatic) and
normal tissues were derived from the same patient.
Whole-genome and WES. Prior to the library construction, 2–3 mg of genomic
DNA from each sample was fragmented using a Covarias sonication system to
mean sizes of B500 bp. After fragmentation, libraries were constructed according
to the Illumina Paired-End protocol. Brieﬂy, the puriﬁed, randomly fragmented
DNA was treated with a mix of T4 DNA polymerase, Klenow fragments, T4
polynucleotide kinase and a nucleotide triphosphate mix to repair the ends by
blunting and phosphorylation. The blunted DNA fragments were subsequently
30-adenylated using the Klenow fragment (30–50exo) and ligated by T4 DNA
ligase to BGI-designed PE Index Adaptors that had been synthesized with
50-methylcytosine in place of cytosine. After each step, the DNA was puriﬁed using
the QIAquick PCR Puriﬁcation Kit (Qiagen). For exome sequencing, 3 mg genomic
DNA from each sample was fragmented and ligated PE Index Adaptors then
captured with SureSelect Human All Exon 50Mb Kit as described in the protocol
for the SureSelect Target Enrichment System for an Illumina Paired-End
Sequencing Library. All the constructed libraries were sequenced on HiSeq 2000
platform using 2 100-bp paired-end reads.
After removing sequencing reads containing adaptor sequence and low-quality
reads, which have too many Ns (410%) and low-quality base (450% bases
with quality o5), the high quality paired-end reads were gapped aligned to the
UCSC human reference genome (hg19) using BWA55. After the processes
of ﬁxing mate information, adding read group information, Picard (v1.54)
(http://picard.sourceforge.net/) was used to mark duplicate reads caused by PCR.
Then local realignment of the BWA aligned reads was carried out by using the
Genome Analysis Toolkit (GATK)56.
After fundamental analysis, the potential somatic substitutions were identiﬁed
by MutTect19 with default parameter based on paired alignment ﬁles (primary and
normal, metastasis and normal).The raw lists of somatic indels were detected by
Platypus20 based on default parameter. After this process, germline variants could
be effectively removed.
The Somatic CNVs of sample pairs with WGS were identiﬁed by modiﬁed-
method based on Segseq algorithm and copy number gain or loss status using
thresholds ofZ2.5 copies for gain andr1.5 copies for loss. The somatic CNVs of
sample pairs with WES were identiﬁed by the CONTRA57 algorithm. In the
CONTRA algorithm, base-level log-ratios between the case and control were taken
into consideration to eliminated GC bias and imbalanced library size effect. Target
regions of o10bp with depth of coverage o10 were discarded. For the remaining
regions, the mean log-ratio was calculated and the signiﬁcant P value was then
assigned. Then the circular binary segmentation was applied to the log-ratios of
regions with default settings. Segmentation results were then used for the
subsequent analysis. GISTIC37 algorithm was used to infer recurrently ampliﬁed or
deleted genomic regions, using copy numbers in 100-kb windows. G scores
represented the frequency and amplitude of ampliﬁcations or deletions of each
genomic region.
Somatic SVs were identiﬁed by a modiﬁed pipeline developed based on
CREST58 algorithm. All the detected variants were subsequently annotated by
ANNOVAR59.
Validation of somatic mutations. Identiﬁed mutations were validated either
by mass spectrum or target region captured resequencing. For mass spectrum
validation, speciﬁc primers were designed for PCR ampliﬁcation and base
extension that covered the mutation sites. Genotyping assay and base calling of
successfully ampliﬁed products were performed on the MassArray platform of
Sequenom. Ultra-deep target region sequencing on a set of 51 selected genes was
used to evaluate the validation status of identiﬁed SNPs and indels. One microgram
of genomic DNA from each sample for validation was used for hybrid capture and
library construction. Libraries were then sequenced on HiSeq 2500 platform using
2 100 bp paired-end reads sequencing.
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Figure 6 | Therapeutic targeting in lung adenocarcinomas. Somatic mutations, copy number alterations and translocations affecting genes that are
regarded as targets of speciﬁc antibodies or kinase inhibitors. Somatic mutations only consist of recurrent mutations in this cohort or mutations previously
reported in the COSMIC database. Primary tumours and metastatic tumours with at least one alteration are shown.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10131
10 NATURE COMMUNICATIONS | 6:10131 | DOI: 10.1038/ncomms10131 | www.nature.com/naturecommunications
Mutational signature analysis. Mutational signature analysis was performed
as follows: brieﬂy, the computational framework for mutational signatures
deciphering was downloaded from http://www.mathworks.com/matlabcentral/
ﬁleexchange/38724. Mutational signatures were extracted from the WGS data
of 24 primary tumours and corresponding metastasis tumours as follow:
(1) Somatic base substitutions of each data set were classiﬁed into 96 possible
mutated trinucleotides, as 6 types of substitution (C:G4A:T, C:G4G:C,
C:G4T:A, T:A4A:T, T:A4C:G and T:A4G:C) 4 types of 50 base (A, C, G,
T) 4 types of 30 base (A, C, G, T), to generate mutational catalogue. Then the
prevalence of somatic mutations was calculated for each type of substitution.
(2) Signatures of 15 mutational processes from the mutational catalogue were
deciphered by the mutational signature framework. The number of signature
extracted (N) is determined by estimating the signature reproducibility and
reconstruction error rate and as described by Alexandrov et al.60, N here is the
number where the lowest reconstruction error is achieved without decreasing the
reproducibility. (3) The minimal set of mutational signatures was then determined
to optimally explain the proportion of each mutation type found in the catalogue,
based on reproducibility of their signatures and low error for reconstructing
the original catalogue. Somatic mutations of WGS from 22 European lung
adenocarcinomas were downloaded from ftp://ftp.sanger.ac.uk/pub/cancer/
AlexandrovEtAl. Pearson correlation analysis was performed to compare signature
patterns between primary and metastasis tumours in this study and those of
European lung adenocarcinomas. Contributions of distinct signatures in individual
tumour were also proﬁled and Pearson correlation analysis was performed to
compare the signature contributions between paired primary and metastasis
tumours21,60.
Identiﬁcation of potential signiﬁcantly mutated genes. Considering the high
background mutation rate in lung adenocarcinoma, analysis of signiﬁcance of
mutated genes was performed through two statistical procedures. First, a cancer
driver gene prediction model23 was used to calculate the signiﬁcance of detected
mutations for each mutated gene. The mutation prevalence and functional impact
was evaluated by this approach, and a background distribution of mutation score
was assigned to each gene then. Taking together the background distribution of
mutation score and test statistics of observed mutation scores across samples, a
P value was computed for each gene and adjusted using the Benjamini–Hochberg
method to further determine the false discovery rate (FDR). Only genes with FDR
(q-value) o0.1 were selected for following analysis. A subsequent prediction of
signiﬁcantly mutated genes was performed using the MutSig25 algorithm and genes
with FDR q-value o0.1 were regarded as signiﬁcant.
Transcriptome sequencing. About 20mg total RNA from each sample was treated
with RNase-free DNase I for 30min at 37 C (New England BioLabs) to remove
residual DNA. Beads with oligo (dT) were used to isolate poly (A) mRNA.
First-strand complementary DNA (cDNA) was synthesized using random
hexamer-primer and reverse transcriptase (Invitrogen). The second-strand cDNA
was synthesized using RNase H (Invitrogen) and DNA polymerase I (New England
BioLabs). Then the cDNA libraries were prepared following the manufacturer’s
instructions and were sequenced on the HiSeq 2000 platform.
The raw reads ﬁltering process include three criteria: (1) Remove reads with
sequence adaptors; (2) Remove reads in which unknown bases are 410%;
(3) Remove low-quality reads, which have 450% in one read. All subsequent
analyses were based on clean reads.
Mapping clean reads to the human genome and transcriptome, the reference
sequences used were genome and transcriptome sequences downloaded from the
UCSC website (version hg19). The Clean data were respectively aligned to the
reference genome and transcriptome by SOAP2. Less than ﬁve mismatches were
allowed for each read in the alignment.
The gene expression level is calculated by using RPKM method (reads per kb
transcriptome per million mapped reads), and the formula is shown as follows:
RPKM ¼ 10
6C
NL=103
ð1Þ
In which C is the number of reads that are uniquely mapped to the given gene,
N stands for the total number of reads that are uniquely aligned to all genes and L
is the total length of exons from the given gene.
Identiﬁcation and validation of fusion genes. Soapfuse61 was used to identify
fusion genes between paired tumour and normal samples from transcriptome
sequencing using the default parameters. Reads were mapped against the human
reference genome sequence (hg19) and annotated transcript. SOAPfuse then
detected two kinds of reads to identify potential fusion events: span-reads that were
deﬁned as paired-end reads mapping to two distinct genes and junction reads that
covered the exact junction sites, after ﬁltering duplicated reads a candidate fusion
event was determined if more than two reads support the paired-end connection
and junction site. WGS data of samples harbouring fusion genes were also analysed
to conﬁrm fusion events that were generated by genomic rearrangements with
breakpoints in intron or exon regions. Conﬁrmed fusion events were validated at
both RNA and DNA level by PCR and Sanger sequencing.
Concurrence and mutual exclusion analysis. Concurrence and mutual exclusion
analysis was performed on signiﬁcantly mutated genes, signiﬁcant copy number
variations and translocations or fusion events involving ALK, as well as clinical
features such as smoking, age and metastasis status. Signiﬁcance was calculated by
Fisher’s exact test.
Pathway and network analysis. Pathway enrichment analysis was carried out by
using WebGestalt62 to investigate the distribution of genes affected by somatic
mutations, CNAs and genomic rearrangements within the KEGG database. To
inquire the potential interaction network of altered genes, Cytoscape (V3.1.1)
software63 (http://www.cytoscape.org/) was used to identify pathways and network
patterns related to cancer through the reactome functional interaction plugin64.
Real-time RT–PCR assay. Total RNAs of lung cancer cells and lung
adenocarcinoma specimens were extracted using Trizol reagent (Invitrogen). The
quality and quantity of RNA were determined by agarose gel electrophoresis and
photospectrometry. One microgram of RNA was used for cDNA synthesis using
the RT System (Promega) according to the manufacturer’s instructions. Real-time
PCR was performed using GoTaq qPCR Master Mix (Promega). Thermal cycling
conditions were as follow: 1 step for 10min at 95 C followed by 40 cycles at 95 C
for 15 s and at 60 C for 1min. The quality of the PCR products was monitored
using post-PCR melting curve analysis. Relative mRNA levels were calculated with
DDCt methods using b-actin for normalization.
Immunohistochemistry. Immunohistochemistry analysis of IQGAP3 in the
primary tumours of lung adenocarcinoma was carried out using a standard
avidin–biotin–peroxidase technique. In brief, the formalin-ﬁxed, parafﬁn-
embedded tissue sections were deparafﬁnized and rehydrated through xylene,
graded ethanol and water.
The endogenous peroxidase activity was blocked by incubating the sections
in 3% hydrogen peroxide for 15min, and heat-induced epitope retrieval was
performed by incubating the sections in boiling sodium citrate buffer (10mM
sodium citrate, 0.05%Tween-20, pH 6.0) for 20min in microwave. Then the
sections were blocked with 10% normal goat serum in PBS for 10min at room
temperature, and incubated with primary antibody against IQGAP3 (1:80,
ab151437, Abcam, USA) diluted in 1% BSA (Zhongshanjinqiao, Beijing, China)
overnight at 4 C.The Maixin Detection System Peroxidase/DAB, Rabbit/Mouse kit
was applied to determine immunoreactivity according to the manufacturer’s
instructions, with 1:50 dilutions of DAB Chromogen to HRP Substrate Buffer.
Sections were then washed, and counterstained for 30 s in ﬁltered Harris
Haematoxylin (Zhongshanjinqiao). After washing with PBS and dehydration with
graded ethanol followed by xylene, the sections were mounted in neutral balsam
(Zhongshanjinqiao).The slides were viewed and images were captured using Nikon
Eclipse 80i microscope with NIS-Elements F software. Analysis of cytoplasm
staining was performed by two pathologists independently through measuring the
percentage of positively stained tumour cells. A consensus was reached for intensity
by taking the mean if scores were within 20% of each other; otherwise, images were
reviewed and a consensus reached.
Statistical analysis for clinicopathological data. The correlation of IQGAP3
expression with clinicopathological characteristics was determined by Pearson’s
w2-test. The differences of IQGAP3 mRNA and protein between tumours and
normal tissues were tested by student’s t-test and Wilcoxin signed rank test,
respectively. Overall survival and disease-free survival were estimated using
Kaplan–Meier method with log rank test. The prognostic signiﬁcance of IQGAP3
was evaluated by Cox regression model with forward likelihood ratio (LR) method.
All statistical analyses were performed using GraphPad Prism 5 and SPSS16.0.
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